# Trump Signs Order to Fast-Track Psychedelic Research | Euronews – CED Clinic > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/psychedelic-research-acceleration-trump-executive-order/ > **Published:** 2026-04-19T13:06:21-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:17:56-04:00 > **Clinical Summary:** Explore how psychedelic research acceleration under Trump’s order could impact clinical trials and FDA approvals for mental health treatments. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic PolicyPsychedelics[Mental Health](https://cedclinic.com/cannabis-psychiatric-research-findings-depression-anxiety/)[Clinical Trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/)Ptsd Why This Matters Fast-tracking psychedelic research could accelerate evidence generation for treatment-resistant psychiatric conditions where current therapies show limited efficacy. This policy shift may influence [FDA approval](https://cedclinic.com/medicare-cannabis-reimbursement-policy-fda-approval/) timelines and clinical trial accessibility for psilocybin, MDMA, and other investigational psychedelics. Clinical Summary The executive order aims to expedite research pathways for psychedelic compounds currently in clinical development for psychiatric disorders. Several psychedelics are in Phase II/III trials for conditions including treatment-resistant depression, PTSD, and end-of-life anxiety. The order likely addresses regulatory bottlenecks rather than changing fundamental safety or efficacy requirements. Clinical evidence remains mixed, with promising signals for specific indications but significant methodological challenges in blinded studies. Dr. Caplan’s Take “This is about research acceleration, not clinical availability—patients still need evidence-based care today. The real question is whether faster timelines compromise the rigorous safety data we need for compounds with profound neuropsychiatric effects.” Clinical Perspective 🧠 Clinicians should maintain current evidence-based approaches while monitoring emerging trial data. Patients inquiring about psychedelic treatments should understand this affects research timelines, not immediate access. Continue established protocols for treatment-resistant conditions while staying informed about legitimate clinical trial opportunities. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Trump%20signs%20order%20to%20fast-track%20research%20on%20psychedelic%20drugs%20%7C%20Euronews%20-%20CED%20C...%20%40drcaplan&url=https%3A//cedclinic.com/trump-signs-order-to-fast-track-research-on-psychedelic-drugs-euronews/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//cedclinic.com/trump-signs-order-to-fast-track-research-on-psychedelic-drugs-euronews/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Trump%20signs%20order%20to%20fast-track%20research%20on%20psychedelic%20drugs%20%7C%20Euronews%20-%20CED%20C...%20--%20via%20%40drcaplan.bsky.social%20https%3A//cedclinic.com/trump-signs-order-to-fast-track-research-on-psychedelic-drugs-euronews/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://cedclinic.com/trump-signs-order-to-fast-track-research-on-psychedelic-drugs-euronews/](https://cedclinic.com/psychedelic-drug-research-acceleration-trump-order/) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating of this news?](#What_is_the_clinical_relevance_rating_of_this_news) - [What topics does this article cover?](#What_topics_does_this_article_cover) - [Why is this article marked as “New”?](#Why_is_this_article_marked_as_8220New8221) - [What does “Notable Clinical Interest” mean for practitioners?](#What_does_8220Notable_Clinical_Interest8221_mean_for_practitioners) - [How does this relate to mental health treatment?](#How_does_this_relate_to_mental_health_treatment) - [Related](#Related) ## FAQ #### What is the clinical relevance rating of this news? This article has a CED Clinical Relevance rating of #70, which indicates “Notable Clinical Interest.” This means it contains emerging findings or policy developments that are worth monitoring closely by [healthcare professionals](https://cedclinic.com/women-reproductive-health-cannabis-applications/). #### What topics does this article cover? The article covers policy developments, psychedelics, [mental health](https://cedclinic.com/cannabis-psychiatric-research-findings-depression-anxiety/), and [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/). It appears to be part of cannabis news coverage from CED Clinic. #### Why is this article marked as “New”? The “New” designation indicates this is recently published content. This suggests the information contains current developments that [healthcare professionals](https://cedclinic.com/women-reproductive-health-cannabis-applications/) should be aware of. #### What does “Notable Clinical Interest” mean for practitioners? “Notable Clinical Interest” suggests this contains information that could impact [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/). Healthcare providers should monitor these developments as they may influence treatment approaches or policy changes. #### How does this relate to mental health treatment? Given the mental health and psychedelics tags, this likely discusses emerging treatments or policy changes affecting mental health care. The clinical trial aspect suggests there may be research developments relevant to mental health practitioners. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Trump signs order to fast-track research on psychedelic drugs | Euronews](https://cedclinic.com/psychedelic-drug-research-acceleration-trump-order/) Detailed coverage of Trump’s executive order aimed at accelerating psychedelic drug research and its potential impact on mental health treatments. [Read More](https://cedclinic.com/psychedelic-drug-research-acceleration-trump-order/) [Trump Signs Order To Accelerate Legal Access To Psychedelics For Patients With Mental …](https://cedclinic.com/accelerate-psychedelic-assisted-therapies-mental-health-access/) Insights into the legal and clinical implications of Trump’s order to speed up access to psychedelics for mental health patients. [Explore Details](https://cedclinic.com/accelerate-psychedelic-assisted-therapies-mental-health-access/) [President Trump signs executive order encouraging research on psychedelic drugs – WCTV](https://cedclinic.com/psychedelic-executive-order-research/) News coverage on the executive order promoting psychedelic drug research and its significance for clinical trials and policy. [Learn More](https://cedclinic.com/psychedelic-executive-order-research/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).